Enterome Bioscience SA, a French company developing diagnostics for diseases linked to the gut microbiome, has raised €10 million in a Series B equity financing from a syndicate led by Seventure Partners and Lundbeckfond Ventures.
The tau pathway is the focus of a new investment by Bristol-Myers Squibb Company which is planning to spend $175 million in cash and potential milestones of $550 million to acquire the privately-owned biotechnology company iPierian Inc.
Silence Therapeutics Plc, a UK company exploring potential therapeutics based on RNA interference, has raised £11.4 million in a private equity placement with institutional investors and management to support its ongoing research and development activities.
MorphoSys AG is set to install its latest antibody discovery technology at a unit of Temple University in Philadelphia, Pennsylvania, US as part of an alliance aimed at identifying new antibodies f
Pfizer Inc’s potential bid for AstraZeneca Plc appeared to be gaining traction following a Pfizer conference with analysts on 28 April and a formal declaration of interest to the London Stock Exchange earlier the same day.
Pharming Group NV has raised €14.7 million with a private placement of its shares and warrants with existing institutional shareholders to support the expected launch of Ruconest, a treatment for hereditary angioedema.
The French biotechnology company TxCell SA has secured €16.2 million in an initial public offering of its shares on the Euronext stock exchange in Paris, enabling it to advance the clinical development of its lead product Ovasave for refractory Crohn’s disease.
Novartis, GlaxoSmithKline Plc and Eli Lilly and Company announced a fundamental reshaping of their businesses on 22 April while yet-to-be denied rumours circulated on global stock markets of an imminent bid by Pfizer Inc for AstraZeneca Plc.
OxThera AB, a privately-held Stockholm-based biotechnology company, has raised SEK 70 million (€7.5 million) to finance clinical development of Oxabact, a treatment for primary hyperoxaluria (PH), a genetic disorder that can lead to kidney failure.
BioAlliance Pharma SA of France has reached an agreement with Topotarget A/S of Denmark to merge, enabling the companies to jointly exploit their oncology portfolios. Shareholders of BioAlliance will hold about two-thirds of the merged company.